Intravitreal Injections in the Ovine Eye
July 5th, 2022
3.9K views
Intravitreal injections were performed in the sheep eye with the aim of delivering viral-mediated gene therapy to the retina.
Overview
This article presents a protocol for performing intravitreal injections in the sheep eye, which serves as a model for human ocular treatments. The method aims to deliver viral-mediated gene therapy to the retina, specifically targeting retinal degeneration.
Key Study Components
Area of Science
- Gene therapy
- Ophthalmology
- Animal models
Background
- Intravitreal injections are less invasive than other ocular injection methods.
- Sheep are used as a model due to similarities with the human eye.
- The study addresses retinal degeneration caused by neuronal ceroid lipofuscinoses.
- Gene therapy products can be effectively delivered using this method.
Purpose of Study
- To demonstrate a protocol for intravitreal injections in sheep.
- To explore the efficacy of gene therapy for retinal conditions.
- To provide a less invasive alternative for ocular treatments.
Methods Used
- Sheep are anesthetized prior to the procedure.
- The eye is disinfected using a povidone iodine solution.
- A sterile surgical drape is positioned over the eye.
- Intravitreal injections are performed to deliver the therapeutic agents.
Main Results
- The protocol successfully delivers gene therapy to the retina.
- Intravitreal injections show potential for treating retinal degeneration.
- The method is demonstrated to be effective in a sheep model.
- Results indicate a less invasive approach to ocular therapy.
Conclusions
- Intravitreal injections are a viable method for gene therapy delivery.
- This approach can be adapted for human applications.
- Further research is warranted to explore long-term effects.
Frequently Asked Questions
What are intravitreal injections?
Intravitreal injections are a method used to deliver therapeutic agents directly into the vitreous humor of the eye.
Why use sheep as a model for human eye studies?
Sheep eyes have anatomical and physiological similarities to human eyes, making them suitable for research.
What is the significance of using gene therapy for retinal degeneration?
Gene therapy has the potential to address the underlying causes of retinal degeneration, offering new treatment options.
How is the eye prepared for an intravitreal injection?
The eye is disinfected with a povidone iodine solution before the injection to minimize infection risk.
What are the advantages of intravitreal injections compared to other methods?
Intravitreal injections are less invasive and can deliver therapeutic agents directly to the target area in the retina.
Executive Industry Relevance
Intravitreal injection protocols in the ovine eye provide a translationally relevant preclinical model for evaluating retinal gene therapies and other intravitreal therapeutics. This approach enables predictive assessment of safety, efficacy, and retinal tissue response in a system closely mirroring human ocular anatomy. The method supports critical decision points in ophthalmic drug development pipelines, particularly for gene therapy and biologic modalities targeting retinal degeneration.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables functional interrogation of therapeutic hypotheses in a large-animal model with human-like ocular features.
- Supports biological de-risking by providing in vivo evidence of retinal response to candidate agents.
- Facilitates mechanistic validation of gene therapy vectors and delivery strategies.
Screening & Assay Development
- Establishes a reproducible protocol for intravitreal administration, supporting downstream assay standardization.
- Generates quantitative outputs such as retinal thickness and electroretinography for objective efficacy assessment.
- Prepares validated biological systems for scalable compound or vector evaluation.
Translational & Preclinical Research
- Aligns preclinical testing with disease-relevant endpoints, including retinal structure and function preservation.
- Enables continuity from discovery through IND-enabling studies by modeling human ocular delivery routes.
- Supports risk-adjusted advancement of gene therapy candidates based on translationally predictive data.
Pipeline & Workflow Integration
This intravitreal injection protocol positions the ovine model as a bridge from early discovery to preclinical validation for retinal therapeutics.
- Discovery Biology: Provides a platform for hypothesis testing and pathway clarification in retinal disease models.
- Screening: Delivers standardized, reproducible administration for comparative evaluation of therapeutic candidates.
- Analytics: Enables quantitative measurement of retinal function and structure to inform go/no-go decisions.
- Translational Research: Facilitates alignment with clinical delivery routes and endpoints for gene therapy programs.
- Enterprise Reuse: Offers a reusable, scalable protocol for diverse intravitreal agents and modalities.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in retinal therapeutic development.
- Operational Value: Standardizes intravitreal delivery and readouts for cross-study comparability.
- Strategic Value: Improves capital efficiency by enabling earlier de-risking of ocular drug candidates.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of gene therapy and biologic assets.
Implementation Considerations
- Requires expertise in large-animal ophthalmic procedures and anesthesia.
- Needs access to surgical instrumentation and quantitative retinal analytics (e.g., electroretinography, histology).
- Demands cross-team standardization for protocol reproducibility and data comparability.
- May require adaptation for different therapeutic modalities or disease models.
- Practical limitations include model-specific anatomical considerations and resource requirements.
Biopharma FAQs
Why does null hypothesis testing matter for intravitreal gene therapy validation?
Null hypothesis testing enables objective assessment of whether intravitreal gene therapy produces statistically significant preservation of retinal structure and function compared to untreated controls, supporting robust target validation in preclinical models.
How does independent variable isolation in ovine intravitreal injection studies support discovery pipelines?
By treating one eye and using the contralateral eye as an internal control, the protocol isolates the effect of the therapeutic intervention, enhancing interpretability and confidence in discovery-stage findings.
What do quantitative dependent variable measurements like retinal thickness enable in preclinical evaluation?
Quantitative measurements such as retinal thickness and electroretinography provide objective, reproducible endpoints for comparing treatment efficacy and informing advancement decisions in the development pipeline.
Why are replication requirements critical for cross-functional collaboration in intravitreal delivery studies?
Replication ensures that observed effects are consistent and reproducible across studies and teams, facilitating reliable data sharing and collaborative decision-making in multi-disciplinary R&D environments.
What statistical analysis capabilities are required before implementing ovine intravitreal injection protocols?
Robust statistical analysis is needed to compare treated and control eyes, assess significance of functional and structural outcomes, and support data-driven progression of therapeutic candidates.
